All lobbying filings

The McManus Group

The McManus Group filed a Q3 report for Royal Biologics on October 20, 2025, reporting $40,000 in lobbying income.

Lobbying for Royal Biologics · OrthoBiologics and life science company

As filed: THE MCMANUS GROUP for ROYAL BIOLOGICS.

All filings by The McManus Group · Everything Royal Biologics has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$40,000

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P). Skin Substitute Access and Payment Reform Act of 2025 (S. 2561).

Bills named in this filing 1

S. 2561
Skin Substitute Access and Payment Reform Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.